UNSPSC 51333104: Carvotroline

This classification denotes an antipsychotic agent with the molecular formula C18H18FN3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1Q63WWP8G5, chemically known as 1h-pyrido(4,3-b)indole, 8-fluoro-2,3,4,5-tetrahydro-2-(2-(4-pyridinyl)ethyl)- but generally known as carvotroline, which bears US NIH Compound Identifier 72038. Carvotroline most often comes in base and hydrochloride forms. European Medicines Agency schedules Carvotroline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06154MIG.

UNSPSC 51333104 Carvotroline is a Commodity code covering pharmaceutical products being procured by state and local health agencies, typically through public health departments, HHS commissions, and cooperative purchasing alliances. State and local governments buy generic pharmaceuticals, over-the-counter products, and harm-reduction medications such as naloxone under this code, sourced either directly from manufacturers or through authorized wholesalers. The issuing bodies include state health and human services commissions, county health departments, and multistate cooperative purchasing organizations that aggregate procurement across multiple jurisdictions; Seminole County, Florida and the Texas Health and Human Services Commission are recent active buyers.

Recent activity spans Florida, Texas, and Minnesota. Seminole County issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023—a mature procurement with fixed-fee pricing, two-year initial term, and one-year renewal option. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administered by the Minnesota Department of Administration issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities, with responses due March 26, 2026; vendors must supply through three authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act requirements, with awards effective July 1, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels, signaling early-stage strategic procurement development rather than immediate competitive bidding.